28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder
Clinical trial NCT04944901 · COMPLETED
Trial details
- NCT number
- NCT04944901
- Sponsor
- Scioto Biosciences, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-02
- Primary completion
- 2022-03-03
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.